Figure 1 | Scientific Reports

Figure 1

From: BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine

Figure 1

A high throughput chemical screen reveals resistance of BRCA1-mutant breast cancer cell lines to MEK inhibitors.

(a) A library of 198 FDA-approved and experimental drugs was tested against a panel of BRCA1-mutant (1–4) and BRCA1-wild-type (5–8) cell lines. Relative cell viability was measured using CellTiter-Blue fluorescent metabolic assay after three days of incubation and presented as a heat map of differential drug sensitivity scores (dDSS). (b) Differential DSS scores for MEK1/2 inhibitors and 6-thioguanine are highlighted. Cell line names are shown above. Mut, BRCA1 mutant; WT, BRCA1 wild type.

Back to article page